Please assess the completion status of the following clinical trial:

Trial Title: Fulvestrant in Treating Patients With Recurrent Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Early recurrent disease, defined by 1 of the following criteria:~    * Prostate-specific antigen (PSA) ≥ 2.0 ng/mL AND clearly rising within the past 3 months for patients who underwent prior prostatectomy with or without radiotherapy~   * PSA ≥ 4.0 ng/mL AND clearly rising from the lowest value obtained within the past 6 months for patients who underwent prior definitive radiotherapy only~* No evidence of clinical recurrence,\* as defined by the following criteria:~  * Digital rectal exam negative~ * No local recurrence by CT scan or MRI of the pelvis~ * No evidence of bone metastasis by bone scan NOTE: \*Prostascint scan results are not considered evidence of recurrence~* Underwent prior curative treatment comprising radical prostatectomy with or without adjuvant radiotherapy OR definitive radiotherapy alone~* Testosterone (total or free) \> than lower limit of normal~PATIENT CHARACTERISTICS:~Age~* Any age~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* WBC \> 3,500/mm\^3~* Platelet count \> 100,000/mm\^3~* No history of bleeding diathesis~Hepatic~* INR \< 1.6~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* ALT or AST ≤ 2.5 times ULN~* No severe hepatic impairment that would preclude study participation or compliance~Renal~* Creatinine ≤ 2.0 mg/dL~* No severe renal impairment that would preclude study participation or compliance~Cardiovascular~* No unstable or uncompensated cardiac condition that would preclude study participation or compliance~Pulmonary~* No unstable or uncompensated respiratory condition that would preclude study participation or compliance~Other~* No history of hypersensitivity to active or inactive excipients of fulvestrant (e.g., castor oil)~* No other severe condition that would preclude study compliance (e.g., abuse of alcohol or drugs or psychotic states) or participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* More than 6 months since prior neoadjuvant or adjuvant androgen deprivation therapy or luteinizing hormone-releasing hormone antagonist therapy~* No other prior or concurrent hormonal therapy~Radiotherapy~* See Disease Characteristics~* No concurrent radiotherapy~Surgery~* See Disease Characteristics~Other~* More than 4 weeks since prior experimental drug treatment~* No concurrent anticoagulant therapy except antiplatelet therapy~* No other concurrent therapy for prostate cancer~* No other concurrent therapy known or suspected of altering androgen metabolism or androgen levels

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fulvestrant (Type: EXPERIMENTAL): Fulvestrant will be provided as 250 mg in 5 mL as a pre-tilled syringe. Fulvestrant will be administered as 500 mg, that is, 2 injections of 5 mL, one into each buttock im on day 0. A single 250 mg in 5 mL injection will be administered on day 14 followed by a single 250 mg in 5 mL dose on day 28 and monthly thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).